Imatinib, cytokines and interstitial lung disease in a patient with primary myelofibrosis

Annals of Hematology

Volumn 89, Issue 8, 2010, Pages 829-831

  Robibaro, Bruno ^a   Kropfmueller, Anna ^a   Prokop, Mathias ^b   Haber, Paul ^a   Gisslinger, Heinz ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; GAMMA INTERFERON; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; VASCULOTROPIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTERIAL GAS; BLOOD GAS ANALYSIS; BONE MARROW BIOPSY; BRONCHIECTASIS; CASE REPORT; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; HYPOXEMIA; INTERSTITIAL PNEUMONIA; LETTER; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG DIFFUSION; LUNG FUNCTION TEST; LUNG INFILTRATE; LUNG LESION; MALE; MYELOID METAPLASIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLENOMEGALY; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT DURATION; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; INTERSTITIAL LUNG DISEASE; MIDDLE AGED; PATHOLOGY;

CYTOKINES; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PIPERAZINES; PRIMARY MYELOFIBROSIS; PYRIMIDINES;

EID: 77954685766     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0884-6     Document Type: Letter

References (11)

1. Ohnishi K, Sakai F, Kudoh S, Ohno R (2006) Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20:1162-1164
2. Musolino C, Calabro' L, Bellomo G, Martello F, Loteta B, Pezzano C, Rizzo V, Alonci A (2002) Soluble angiogenic factors: Implications for chronic myeloproliferative disorders. Am J Hematol 69:159-163
3. Kikuchi K, Kubo M, Kadono T, Yazawa N, IHN H, Tamaki K (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Brit J Dermatol 139:1049-1051
4. Dirix LY, Vermeulen PB, Pawinski A, Prové A, Benoy I, De Pooter C, Martin M, Van Oosterom AT (1997) Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Brit J Cancer 76:238-243
5. Bran B, Bran G, Hörmann K, Riedel F (2009) The plateletderived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol 34(1):255-261
6. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H (2007) Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 35:1266-1271
7. Aswald JM, Lipton JH, Aswald S, Messner HA (2002) Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia. Cytokines Cell Mol Ther 7:143-149
8. Cristofanilli M, Morandi P, Krishnamurthy S, Reuben JM, Lee BN, Francis D, Booser DJ, Green MC, Arun BK, Pusztai L, Lopez A, Islam R, Valero V, Hortobagyi GN (2008) Imatinib mesylate (Gleevec®) in advanced breast cancer expressing C-Kit or PDGFR-β: Clinical activity and biological correlations. Ann Oncol 19:1713-1719
9. Chaudhary NI, Roth GJ, Hilberg F, Müller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE (2007) Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29:976-985
10. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE (2005) Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201:925-935
11. Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas OA, Linkesch W (2002) Treatement of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI 571 results in marked regression of bone marrow fibrosis. Blood 99:281-283